MacroGenics earmarks $580M for ADC tech; Domainex, nonprofit team up on Parkinson's program
Synaffix and MacroGenics have signed a deal to codevelop and commercialize a clinical platform for antibody-drug conjugates to fight cancer.
Synaffix will license out its GlycoConnect antibody conjugation platform, polar spacer technology and toxSYN linker payloads. In return, it will get $586 million in upfront and milestone payments across the three programs and is eligible for royalties on commercial sales.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters